Daclatasvir acts as a highly selective inhibitor of the NS5A replication complex for hepatitis C. Perturbing viral protein production effectively disrupts the lifecycle of specific viral strains.
Daclatasvir belongs to the class of direct-acting antiviral agents that target the hepatitis C virus. It is designed to interrupt a crucial step in the viral replication cycle, helping to reduce the amount of virus in the bloodstream. The compound appears in several treatment regimens approved for use in Singapore, including the combination product Natdac. Its role as an active substance is central to the therapeutic effect of these antiviral medicines.
In Singapore, Daclatasvir is available as a component of fixed-dose combinations such as Natdac, which pairs the molecule with other antivirals to simplify dosing. Both generic and branded formulations are distributed under the oversight of the Health Sciences Authority. The medication is supplied in tablet form, and each tablet contains a specific amount of Daclatasvir that aligns with the approved treatment protocols. Patients may encounter the ingredient listed on the packaging as “Daclatasvir” or by its international non-proprietary name.
The primary medical use of Daclatasvir-containing products is for chronic infection with hepatitis C virus (HCV). It is frequently prescribed for adults with genotypes 1, 2, 3, 4, 5 or 6, where it works alongside other antivirals to achieve viral suppression. The medication can also be part of regimens used in patients with liver fibrosis or early cirrhosis, aiming to slow disease progression. Because the drug targets the virus directly, it is suitable for individuals who have not responded to earlier therapy options. Treatment plans often consider the patient’s overall health status and any co-existing conditions.
Daclatasvir interferes with a protein that the hepatitis C virus requires to assemble new viral particles. By binding to this protein, the compound prevents the virus from completing its replication cycle, leading to a gradual decline in viral load. The action is specific to the virus, which helps limit effects on healthy cells. This targeted approach contributes to the overall success of antiviral regimens that include the substance.
Commonly reported sensations include fatigue, headache, or a mild rash that usually resolves without medical intervention. These experiences are generally short-lived and may not require any change in therapy.
Rarely, individuals may notice signs such as severe abdominal pain, yellowing of the skin or eyes, or sudden swelling. These symptoms merit immediate medical attention as they could indicate a serious liver-related event.
Pregnant individuals, people with known hypersensitivity to Daclatasvir, and those with advanced liver disease should discuss their situation with a qualified professional before starting therapy. The medication may also be unsuitable for patients with certain metabolic conditions.
Alcohol consumption can increase stress on the liver while taking Daclatasvir-based regimens, so moderation is advisable. Concurrent use of some antiretrovirals, anticonvulsants, or strong enzyme inducers may alter drug levels, affecting effectiveness. Detailed interaction lists are available on the specific product information pages for each medication.
Store tablets in a cool, dry place away from direct sunlight and keep them out of reach of children. Treatment duration varies; some courses last eight weeks while others extend to twelve weeks, depending on the combination used and the patient’s viral genotype. For detailed usage, dosing, and administration, refer to the specific medication's clinical information. Patients should also review the packaging insert for storage recommendations and expiration dates.
This overview provides factual information about Daclatasvir as an active compound and does not constitute medical advice. Individual medicines that contain Daclatasvir, such as Natdac, may differ in formulation, strength, and usage directions. The content is offered for educational purposes only, and liability for clinical decisions is not assumed. Readers are encouraged to read the labeling of their specific product and seek guidance from a qualified healthcare professional.
